| Literature DB >> 25827398 |
Corinne Beinat1, Tristan Reekie2, Samuel D Banister3, James O'Brien-Brown2, Teresa Xie4, Thao T Olson4, Yingxian Xiao4, Andrew Harvey5, Susan O'Connor5, Carolyn Coles5, Anton Grishin5, Peter Kolesik5, John Tsanaktsidis6, Michael Kassiou7.
Abstract
Alpha7 nicotinic acetylcholine receptors (nAChRs) have implications in the regulation of cognitive processes such as memory and attention and have been identified as a promising therapeutic target for the treatment of the cognitive deficits associated with schizophrenia and Alzheimer's disease (AD). Structure affinity relationship studies of the previously described α7 agonist SEN12333 (8), have resulted in the identification of compound 45, a potent and selective agonist of the α7 nAChR with enhanced affinity and improved physicochemical properties over the parent compound (SEN12333, 8).Entities:
Keywords: Acetylcholine receptor; CNS; Structure–activity relationships; α7 nicotinic receptors
Mesh:
Substances:
Year: 2015 PMID: 25827398 DOI: 10.1016/j.ejmech.2015.03.025
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514